Novartis has been serving patients in Indonesia for more than 50 years, through our predecessor companies, Ciba and Sandoz.

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile ...

Having elevated levels of lipoprotein (a), or Lp (a) for short, increases a person’s chances of having a cardiovascular event such as a stroke or a heart attack. It was after having two heart attacks ...

Novartis Entresto® US patent upheld by US Court of Appeals ...

Novartis today announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for PTC518, an HTT mRNA splice modulator with the potential to become the first ...

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio ...

Novartis announced that the FDA has granted Breakthrough Therapy designation to Scemblix® (asciminib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic ...

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant ...

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate ...

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors ...

Novartis announced the company’s financial results for the second quarter and first half of 2024.